Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer

Published:2019-08-30 Issue:4 Volume:77 Page:559-572
ISSN:1420-682X
Container-title:Cellular and Molecular Life Sciences
language:en
Short-container-title:Cell. Mol. Life Sci.

Author:

Zhang Jin,Wang Qianying,Wang Qing,Cao Jiangran,Sun Jiafu,Zhu Zhengmao^ORCID

Funder

National Natural Science Foundation of China

the Natural Science Foundation of Tianjin City of China

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Cellular and Molecular Neuroscience,Pharmacology,Molecular Biology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00018-019-03281-4.pdf

Reference152 articles.

1. Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. https://doi.org/10.1016/s0140-6736(05)66544-0

2. Chen WY, Colditz GA (2007) Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 4(7):415–423. https://doi.org/10.1038/ncponc0851

3. Bernstein L, Lacey JV Jr (2011) Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative? J Natl Cancer Inst 103(6):451–453. https://doi.org/10.1093/jnci/djr046

4. Early Breast Cancer Trialists’ Collaborative G (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352. https://doi.org/10.1016/s0140-6736(15)61074-1

5. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF, Ebctcg (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846. https://doi.org/10.1056/nejmoa1701830

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn;F1000Research;2024-04-25

2. Androgen Receptor Influenced Recurrence Score Correlation in Hormone Positive and HER2 Negative Breast Cancer Indian Patients: A Comparative Approach;Genome Integrity;2024

3. Novel CDK4/6 lnhibitor, WXJ-8 -Exerts Anti-effects Through Cell Cycle in Breast Cancer;Acta Poloniae Pharmaceutica - Drug Research;2023-11-22

4. Preparation and Evaluation of [¹⁸F]AlF-NOTA-PBB for PET Imaging of Cyclin-dependent Kinase 4/6 in Tumors;Molecular Pharmaceutics;2023-08-24

5. Mn(II) Polypyridyl Complexes: Precursors to High Valent Mn(V)=O Species and Inhibitors of Cancer Cell Proliferation;Chemistry – A European Journal;2023-08-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3